Biotechnology
YS Biopharma Announces Receipt of Nasdaq Notice
GAITHERSBURG, Md., Oct. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
HanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
* Sales recorded KRW 33 billion in Q3 2023, an 11 percent increase from the same period in 2022, due to the sustained growth of major products. * 'HL161ANS', HanAll's second anti-FcRn antibody, demonstrated best-in-class potential through the initial outcome of Phase 1 study. * 'HL192', a Nu...
Fapon, LASCCO, Abionic Formed Strategic Collaboration for PSP Sepsis Diagnosis in China
LAUSANNE, Switzerland, Oct. 26, 2023 /PRNewswire/ -- Fapon, a leading life sciences company, entered into a strategic cooperation agreement with two Swiss biotech companies LASCCO SA and Abionic SA, that granted Fapon an exclusive license to utilize the pancreatic stone protein (PSP) biomarker fo...
Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA
SINGAPORE, Oct. 26, 2023 /PRNewswire/ -- On October 26, 2023, Biosyngen's TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA. BST02, a breakthrough product in the field of cell and gene therapy, represents the world's first TIL therapy designed for the tre...
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
* The independent data monitoring committee (IDMC) recommended the continuation of the BBT-877 Phase 2a trial based on the initial clinical data from the first 20 participants dosed with theinvestigational product * No safety concerns were raised based on the evaluation of the data presented ...
First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe
SHANGHAI, Oct. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient inEurope has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company's self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination ...
FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to Clinic
* FDA INTERACT meeting reviews Turn Bio's ERA™ and eTurna™ technologies, approach and plans, paving way toward its IND * Company continues to pace industry's cell regeneration therapy progress MOUNTAIN VIEW, Calif., Oct. 25, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation compa...
SEH Biotechnology: Revolutionizing the Global Beverage and Brewing Industry with Cutting-Edge Water and Biotech from Taiwan
TAIPEI, Oct. 25, 2023 /PRNewswire/ -- Taiwan is renowned for its advanced
semiconductor technology, and it's also a hub for the development of water
technology. SEH Biotechnology Co., Ltd.
AMS BioteQ Makes Debut at Medical Japan 2023: Bringing Innovative Healthcare into New Horizons
TAIPEI, Oct. 25, 2023 /PRNewswire/ -- Medical Japan Tokyo was held grandly from October 11 to 13, gathering medical professionals, manufacturers, medical institutions, and research units from around the world. AMS BioteQ Co., Ltd. made its first appearance in the exhibition and became one of the ...
GC Cell Joins U.S Cancer Moonshot Project
Brining Expertise in NK Cell Therapy to Advance Efforts in Cancer Prevention, early detection, and treatment development ▶ New focus on NK cell therapy for conquering cancer ▶ GC Cell seizes the opportunity to share its cell gene therapy technology and capabilities globally ▶ Development of sol...
Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development
EAST RUTHERFORD, N.J, Oct. 25, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry has been selected as the winner of the API Development Award, presented at the CPhI Pharma Awards inBarcelona, Spain....
Cyrus K. Mirsaidi Named Global CEO to Bridgewest Perth Pharma
--Industry veteran to lead growth for company's CDMO and pharmaceutical supply divisions, NovaCina and LumaCina-- MIAMI and PERTH, Australia, Oct. 25, 2023 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, announced today thatCyrus K. Mirsaidi is ...
TidetronBioworks Illuminated in Global Spotlight at WFF 2023 for Sustainable Power
ROME, Oct. 24, 2023 /PRNewswire/ -- The World Food Forum (WFF) 2023, a global
platform dedicated to addressing the challenges ofSustainable Development Goals
First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO
* Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutation - published in theJournal of Clinical Oncology and accepted by ESMO for oral presentation SEOUL, South Korea, Oct. 24, 2023 /PRNewswir...
Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO
HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The ...
OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product
Visit OBiO at ESGCT 30th Annual Congress in Brussels SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, officially announced an agreement with Refreshgene...
Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards
SINGAPORE, Oct. 24, 2023 /PRNewswire/ -- Juniper Biologics
Cellomics announces Mr. Andy A. Liu as new Group CEO of the Company
Hong Kong, Oct. 24, 2023 /PRNewswire/ -- Cellomics, the leader in liquid biopsy technology for cancer screening and precision diagnosis, is pleased to announce the appointment of Mr.Andy A. Liu as the new Group CEO of the company. With over 25 years of healthcare experience, Mr. Liu brings a weal...
Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO
* KN046 showed encouraging efficacy result especially in OS benefit (mOS: 20.2 months) in advanced NSCLC with EGFR sensitivity mutation who progressed after EGFR-TKI(s). * KN046 showed encouraging efficacy result especially in OS benefit (mOS: 13.3months) in advanced NSCLC with EGFR sensitivi...
LifeSpan Vision Ventures Invests in Matter Bio
NORWALK, Conn., Oct. 24, 2023 /PRNewswire/ -- LifeSpan Vision Ventures today announced an investment in Matter Bio, a longevity holding company focused on preserving genome integrity. Central to the company's philosophy is that as we age, our genome is constantly being damaged by exogenous and en...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24